SI-BONE, Inc. ( SIBN ) NASDAQ Global Market

Cena: 16.22 ( -1.04% )

Aktualizacja 06-23 21:17
NASDAQ Global Market
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 344
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 90%
Ilość akcji: 40 501 000
Debiut giełdowy: 2018-10-17
WWW: https://si-bone.com
CEO: Ms. Laura A. Francis MBA
Adres: 471 El Camino Real
Siedziba: 95050 Santa Clara
ISIN: US8257041090
Opis firmy:

Si-Bone, Inc., firma zajmująca się urządzeniami medycznymi, opracowuje wszczepialne urządzenia używane do rozwiązywania zaburzeń mięśniowo-szkieletowych anatomii sacropelvic w Stanach Zjednoczonych i na arenie międzynarodowej. Oferuje IFUSE, minimalnie inwazyjny system implantu chirurgicznego w celu rozwiązania dysfunkcji i zwyrodnienia stawu krzyżowego, deformacji dorosłych i traumatycznych złamań pierścienia miednicy. Firma dostarcza również IFUSE-3D, implant tytanowy, który łączy trójkątny przekrój implantu IFUSE z zastrzeżoną porowatą powierzchnią i fenestrowaną konstrukcją; oraz IFUSE-TORQ, zestaw implantów z nadrukiem 3D, zaprojektowanym do leczenia pęknięć miednicy i w celu minimalnie inwazyjnego połączenia stawu krzyżowego. Symuje swoich produktów przede wszystkim z bezpośrednimi siłami sprzedaży, a także za pośrednictwem dystrybutorów. Firma została zarejestrowana w 2008 roku i ma siedzibę w Santa Clara w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 691 207 190
Aktywa: 226 998 000
Cena: 16.22
Wskaźnik Altman Z-Score: 4.0
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -25.8
Ilość akcji w obrocie: 90%
Średni wolumen: 458 570
Ilość akcji 42 614 500
Wskaźniki finansowe
Przychody TTM 157 035 000
Zobowiązania: 62 024 000
Przedział 52 tyg.: 11.7 - 20.05
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -0.6
P/E branży: 26.8
Beta: 1.226
Raport okresowy: 2025-08-04
WWW: https://si-bone.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Anthony J. Recupero President of Commercial Operations 902 110 1959
Mr. Anshul Maheshwari Chief Financial Officer 705 693 1980
Ms. Laura A. Francis MBA Chief Executive Officer & Director 1 264 614 1967
Dr. Scott A. Yerby Senior Vice President of Engineering & Chief Technology Officer 0 1968
Saqib Iqbal Director of FP&A and Investor Relations 0 0
Dr. W. Carlton Reckling Chief Medical Officer & Vice President of Medical Affairs 0 1962
Ms. Aimee Einstein Vice President of People & Culture 0 0
Mr. Michael A. Pisetsky Chief Business & Legal Affairs Officer, Secretary and General Counsel 0 1978
Dr. Daniel Joseph Cher Senior Vice President of Clinical & Regulatory Affairs 0 1965
Mr. Jeff Bertolini Senior Vice President of Operations & Information Technology 0 0
Wiadomości dla SI-BONE, Inc.
Tytuł Treść Źródło Aktualizacja Link
4 Recent Earnings Winners Riding Fresh Momentum in May The market turbulence in 2025 has sent stocks zig-zagging up and down. Despite the unavoidable impact of political developments on share price performance, some companies have seen major gains based on a more traditional driver of motion: strong earnings reports. marketbeat.com 2025-05-14 11:30:16 Czytaj oryginał (ang.)
What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now? Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2025-05-13 17:00:50 Czytaj oryginał (ang.)
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet The consensus price target hints at a 41.2% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2025-05-08 15:02:03 Czytaj oryginał (ang.)
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025 SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time. globenewswire.com 2025-05-06 20:09:00 Czytaj oryginał (ang.)
SI-BONE, Inc. (SIBN) Q1 2025 Earnings Call Transcript SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Saqib Iqbal - VP, FP&A, Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America David Turkaly - Citizens JMP Young Li - Jefferies Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Operator Good afternoon. And welcome to SI-BONE's First Quarter 2025 Earnings Conference Call. seekingalpha.com 2025-05-06 02:38:39 Czytaj oryginał (ang.)
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. zacks.com 2025-05-05 22:20:36 Czytaj oryginał (ang.)
SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9% U.S. revenue of $44.8 million, representing growth of 26.6% Gross margin of 79.7%, representing an improvement of 80 basis points Net loss of $6.5 million, representing an improvement of 40.0% Positive adjusted EBITDA of $0.5 million $144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 million Recent Operational Highlights (any comparisons are to the prior year period) Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective October 1, 2025, paying an additional amount up to $3,960 for procedures involving iFuse TORQ TNT SANTA CLARA, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended March 31, 2025. globenewswire.com 2025-05-05 20:09:00 Czytaj oryginał (ang.)
SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript seekingalpha.com 2025-02-25 00:29:37 Czytaj oryginał (ang.)
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.27 per share a year ago. zacks.com 2025-02-24 20:40:59 Czytaj oryginał (ang.)
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 globenewswire.com 2025-02-24 18:09:00 Czytaj oryginał (ang.)
Bruker Appoints Laura Francis to its Board of Directors BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company s. businesswire.com 2025-02-21 10:00:00 Czytaj oryginał (ang.)
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy? Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-02-17 13:06:26 Czytaj oryginał (ang.)
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025 SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com 2025-02-03 18:09:00 Czytaj oryginał (ang.)
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-12-12 12:55:16 Czytaj oryginał (ang.)
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High? The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-11-26 12:55:18 Czytaj oryginał (ang.)
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. globenewswire.com 2024-11-20 18:09:00 Czytaj oryginał (ang.)
SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - BofA Securities Young Li - Jefferies Drew Ranieri - Morgan Stanley Caitlin Cronin - Canaccord Richard Newitter - Truist Securities Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-11-13 00:42:29 Czytaj oryginał (ang.)
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago. zacks.com 2024-11-12 20:26:08 Czytaj oryginał (ang.)
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. globenewswire.com 2024-11-12 18:09:00 Czytaj oryginał (ang.)
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™ The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures globenewswire.com 2024-11-05 10:30:00 Czytaj oryginał (ang.)
Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength? Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2024-10-30 06:35:19 Czytaj oryginał (ang.)
SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024 SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com 2024-10-22 20:09:00 Czytaj oryginał (ang.)
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery. zacks.com 2024-10-14 17:20:22 Czytaj oryginał (ang.)
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws. globenewswire.com 2024-10-10 12:30:00 Czytaj oryginał (ang.)
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 40.3% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-08-26 14:55:30 Czytaj oryginał (ang.)
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA. zacks.com 2024-08-26 13:20:21 Czytaj oryginał (ang.)
SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024 SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. globenewswire.com 2024-08-22 20:30:00 Czytaj oryginał (ang.)
SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion. globenewswire.com 2024-08-20 12:30:00 Czytaj oryginał (ang.)
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.45%: Here's is How to Trade The consensus price target hints at a 64.5% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-08-08 15:00:40 Czytaj oryginał (ang.)
SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024 SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time. globenewswire.com 2024-08-06 12:30:00 Czytaj oryginał (ang.)
SI-BONE, Inc. (SIBN) Q2 2024 Earnings Call Transcript SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Andrew Ranieri - Morgan Stanley Xuyang Li - Jefferies Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-BONE's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-08-06 03:23:05 Czytaj oryginał (ang.)
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago. zacks.com 2024-08-05 22:55:40 Czytaj oryginał (ang.)
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024 Increases 2024 revenue guidance to $165 million - $167 millionExpects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 globenewswire.com 2024-08-05 20:09:00 Czytaj oryginał (ang.)